NTRODUCTION
Despite effective chemotherapy for non-Hodgkin's lymphoma (NHL), more than two-thirds of patients fail to achieve long-term disease free survival. New therapeutic options are needed. RIT is systemic anti-cancer therapy that employs tumor specific, mAb to deliver cytotoxic radionuclides specifically to widespread sites of NHL, thus sparing normal tissue from excessive radiation and the associated toxicity. RIT has proven especially effective for NHL because of the radiosensitivity of NHL, the abundance of target-specific antigens on lymphocyte membranes, and the vascular accessibility of these malignancies (1-7).
The therapeutic potential of RIT in patients with NHL has been shown by a number of investigators utilizing numerous B-cell-specific targets including CD20, CD19, CD22, and HLA-DR10 (Lym-1) (8) (9) (10) (11) (12) (13) (14) (15) . Lym-1 has high affinity against a discontinuous epitope on the beta chain of the HLA-DR10 antigen on the surface of malignant B-lymphocytes (16) . Due to its greater avidity for malignant rather than normal B-cells, Lym-1 preferentially targets malignant lymphocytes. Multiple preclinical and clinical studies with 131 I-, 67 and 90 Y-Lym-1 have demonstrated significant efficacy in relapsed and refractory NHL (8, 9, (17) (18) (19) (20) . In an MTD trial in which heavily pretreated NHL patients were treated with 131 I-Lym-1, 85% had tumor regression, with 19% achieving a complete response (8) .
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From Combined modality therapy (CMT) consists of the concurrent or sequential use of chemotherapy and external beam radiation. CMT has become an increasingly frequent maneuver for treatment of solid tumors and provides an example applicable to RIT for NHL. At least two concepts are involved in CMT: radiosensitization of cancer cells by drugs and the direct cytotoxic effect of chemotherapy. A randomized study in aggressive, but early stage NHL showed superior results with CHOP plus involved field radiation versus CHOP alone (21) .
While demonstrating that the combination of external beam radiation and chemotherapy can be beneficial for patients with NHL, it also illustrates the challenge--external beam radiation, although effective, can only be delivered in high doses to a limited region of the body, while NHL most frequently is widespread. While RIT has proven to be an effective strategy for delivery of tumor-specific radiation, to date, the higher response rates with RIT have not translated into longer overall survival rates compared with treatment using the parent naked, mAb. The efficacy of RIT is limited by toxicity, particularly myelosuppression (7, (22) (23) (24) (25) . We have taken several approaches to improve the therapeutic index of RIT. Newly developed linkers used in the conjugation of the mAb and the radiometal chelator selectively degrade in the liver. One biodegradable linker, DOTA-peptide, has demonstrated a favorable biodistribution profile when utilized with the chimeric L6 mAb in breast xenograft studies (26) and in a phase I clinical trial (27). Another approach to improving efficacy involves the enhancement of tumoricidal effects of RIT by combining RIT with chemotherapeutic agents or as described herein, antibodies (19, (28) (29) (30) Conventional CMT has proven clinically useful for locally advanced malignancies (31) (32) (33) (34) (35) . Combined modality immunotherapy (CMIT) goes one step further by pairing the specific delivery of systemic radiation (i.e.
90
Y-DOTA-peptide-Lym-1) to NHL with the systemic radiation sensitizing effects of an additional agent (i.e. monoclonal antibody). CMIT is further enhanced by its ability to provide continuous radiation at the site of the malignancy--the ultimate in hyperfractionation. Because the radiation is delivered continuously, cancer cells that are hypoxic are more likely to pass through the radiosensitive G 2 /M phase of the cell cycle during the course of treatment, making cure more likely. The benefit of CMIT is provided by the specific targeting of NHL by RIT, and by the timing of the radiosensitizing agent. This allows for the radiation sensitizer to potentially synergize only at the sites targeted by RIT, thus maximizing efficacy and minimizing toxicity. In several different previous xenograft studies synergy has been demonstrated when the radiation sensitizer (Taxol) was given 24-48 hours after RIT (20, 36) .
CD22 is a membrane glycophosphoprotein found on nearly all B-lymphocytes and most B-cell lymphomas. Crosslinking CD22 triggers CD22 tyrosine phosphorylation and assembles a complex of effector proteins that activate the stress-activated protein kinase (SAPK) pathway. In conjunction with interleukins, antigen receptor crosslinking or CD40 crosslinking, CD22 crosslinking provides a co-stimulatory signal in primary B-cells and pro-apoptotic signal in neoplastic B-cells (37) (38) (39) (40) . In addition, CD22 is thought to be a B-cell receptor (BCR) modulator, with recent reports demonstrating both positive and negative effects on BCR-mediated signaling (41) . Recent studies have revealed that several anti-CD22 mAbs (termed HB22.7, HB22.23, and HB22.33) block the interaction of CD22 with its ligand and have distinct functional properties (42) . Crosslinking CD22 on several B cell lymphoma cell lines with these mAbs resulted in a 3 to 5-fold induction of SAPK activity and efficient and effective induction of apoptosis.
Based on these finding we have proposed that the blocking mAb, HB22.7, when given in the appropriate sequence will enhance the efficacy of RIT. Y-DOTA-peptide-Lym-1 was prepared to 98% radiochemical purity with less than 5% aggregate content.
The anti-CD22 mAb, HB22.7, was prepared as previously described (42), using a Protein A Sepharose Fast Flow column (Pharmacia). HB22.7 purity was determined by HPLC and flow cytometry, and found to be >95% pure. The Scatchard analysis (Table 1) Y-2IT-BAD-Lym-1(RIT) and HB22.7 (CMIT) demonstrated greater and more sustained mean tumor volume reduction, which was greatest when HB22.7 was administered simultaneously, and 24 hours after RIT. Surprisingly, Tumor Volume (mm3).
Days after RIT
Using analysis of variance, when examining all treatment groups at day 30 the differences were highly significant (p<0.001). While analysis of volume reduction in all treatment groups at day 60 did not demonstrate significant differences Y-DOTA-peptide-Lym-1 (RIT) alone (green ), anti-CD22 alone (HB22.7) (red ), or three different sequences of RIT and HB22.7 (CMIT), RIT administered 24 prior (blue ), RIT administered simultaneously (turquoise ), and RIT administered 24 hr after (fuchsia ). Tumor volume was assessed three times per week. Represents data compiled from all trials ( Table 2) Figure 3 . The response and cure rate for Rajixenografted mice that were treated as described in Figure 2 . The tumor responses were categorized as follows: C, cure (tumor disappeared and did not regrow by the end of the 84-day study); CR, complete regression (tumor disappeared for at least 7 days but later regrew); PR, partial regression (tumor volume decreased by 50% or more for at least 7 days, then regrew). The data represents results of all independent trials.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Treatment with 90 Y-DOTA-peptide-Lym-1 alone produced 48% PR, 13% CR, and a 13% cure rate. In the CMIT groups, the overall response rate was maximized when HB22.7 and RIT were administered simultaneously generating 45% PR, 15% CR and 25% cure. However in the CMIT groups the cure rate was the greatest (39%) when HB22.7 was administered 24 hours after RIT, which compared favorably to the cure rates observed in the untreated (29%), RIT alone (13%), 24 hours prior (10%) and simultaneous (25%) treatment groups. When examining the degree of response (ranking cure better than CR, better than PR) in all treatment groups using the Kruskal Walis test, the differences were statistically significant (p=0.01).
Individual comparisons against untreated controls were all statistically significant (p<0.05), with the exception of RIT alone (p=0.06) and HB22.7 given 24 hours prior to RIT (p=0.16). While comparison of only active treatment groups (RIT alone, CMIT, and HB22.7) was not significantly different (p=0.18), the CMIT groups treated with HB22.7 simultaneously and after 24 hours had the best observed pattern of response. Interestingly the group treated with HB22.7 alone had the highest cure rate (47%) which was a significant improvement when compared to the untreated controls (p<0.05).
Tumor volume regression and cure rates translated into a similar pattern of survival. At the end of the 84 day study period 38 and 42% of the untreated and RIT alone groups were alive respectively, (Figure 4 ). 
% Surviving Day After RIT
In the CMIT treatment groups, survival increased to 67 and 50% when HB22.7
was administered simultaneously and 24 hours after RIT, respectively. Analysis of survival using Kruskal Walis was significant (p< 0.05) for comparison of all groups. Similar to the response rate analysis, comparison of survival in the RIT groups only did not reveal significant differences (p=0.41), however the best survival in these groups was consistently observed when HB22.7 was administered either simultaneous or 24 hours after RIT.
The best overall survival, 76%, was observed in the group treated with HB22.7 alone, a significant difference when compared to untreated control (p=0.02). 
Toxicity
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Discussion
Raji xenograft studies were designed to determine if the anti-CD22 mAb (HB22.7) would generate additive or synergistic effects when combined with RIT to enhance apoptosis and/or DNA damage induced by low dose-rate radiation.
The Raji xenograft nude mouse model has proven useful when used to assess toxicity and efficacy of RIT using 90 Y-2IT-BAD-Lym-1 RIT alone (19) . Responses in this pre-clinical model translated into significant efficacy in human clinical trials (20, 47 ).
In the study described herein, the addition of the anti-CD22 mAb HB22.7 to HB22.7 was chosen based on in vitro studies demonstrating pro-apoptotic and signaling effects (42) . The treatment dose of HB22.7 utilized was empiric, however it was based on the amount that was shown to be effective at inducing apoptosis in vitro and extrapolating this to the mouse model. In addition, when formulating the dose of HB22.7 consideration was given to the equivalent (when adjusted for body surface area differences in humans versus mice) dose of Rituximab used in human clinical trials. The approximation to the rituximab dose was utilized based on the fact that this is the only naked mAb available that has demonstrated efficacy for the treatment of lymphoma, granted, the optimal dose of rituximab is currently undefined.
The study was designed to assess the efficacy of HB22.7 alone, the combination of RIT and HB22.7 as well as the effect of three different sequence combinations. increased the cure rate to 25% when administered simultaneously with RIT, and to 39% when HB22.7 was administered 24 hours after RIT.
The mechanism by which HB22.7 augments the tumoricidal effects of RIT is an area of active investigation. The mechanism by which apoptotic signals are transferred from the membrane to the nucleus is only partially known. In some cell types this mechanism has been shown to involve the stress-activated protein kinase (SAPK/JNK) system (42) . The SAPK/JNK cascade is a generic signaling system that becomes activated by a variety of stimuli and cellular stress (48) .
Previous studies have shown that exposure of various cell lines to ionizing and UV radiation activated the SAPK cascade downstream of ceramide (49, 50) .
These data suggest that the SAPK/JNK cascade couples membrane and nuclear elements of the apoptotic pathways which become activated by ionizing radiation and other cellular stresses. Previous studies have demonstrated that the proapoptotic effects of the mAb HB22.7 are mediated via the SAPK pathway as well (42) , and that the SAPK pathway is a known apoptotic mediator in B cell lymphomas. We have hypothesized that the sequence dependence of RIT and response from RIT as demonstrated by a longer time to tumor progression compared to RIT alone. However, the addition of RIT to HB22.7 did not improve the overall survival or CR rate, which was best with HB22.7 alone. This suggests that these two antibodies act by invocation of different cellular mechanisms, and may involve both synergistic and antagonistic effects.
The pattern of response to these two agents suggests that HB22.7 required time to work, but continued to exert anti-tumor effects over the 84 day study period.
Therefore, mice that had rapid and substantial early tumor shrinkage secondary to RIT, subsequently also benefited from the later effects of HB22.7. This is similar clinically to "induction" followed by "consolidation" therapy for human hematologic malignancies. This is also a quite useful combination because the late therapeutic effect of HB22.7 does not carry with it additional myelosuppression. Conversely, there was no "long-term" additional efficacy from the addition of RIT to HB22.7 because all of the positive effects of RIT were early, within the first 42 days.
The fact that tumor volume reduction and survival were better for HB22.7 alone than for CMIT groups at the end of the 84 day study, suggests not only that 
